Compare Jumia Technologies AG - ADR (JMIA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Summit Therapeutics Inc — how do they compare? Jumia Technologies AG - ADR trades at $6.28 (market cap $865.90M), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 15.8× Jumia Technologies AG - ADR's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 28 Days and Summit Therapeutics Inc for 16 Days on average.
| JMIA | SMMT | |
|---|---|---|
Market Cap | $865.90M | $13.71B |
Volume | 1,695,227 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $26.38 |
52-Week Low | $5.69 | $12.43 |
Typical Hold Time | 28 Days | 16 Days |
Enterprise Value | $831.54M | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA stock trades at $6.48, down 3.86% today, with a bearish technical outlook from moving averages. The company reported Q2 2026 revenue growth and narrowing losses, with a path to EBITDA breakeven by Q4 2026. Analyst consensus is bullish with a $12.00 price target, but the stock faces headwinds from persistent negative earnings and high valuation multiples.
The investment case hinges on JMIA's operational improvements and capital infusion, but risks include sustained cash burn and competitive pressures in African e-commerce. Upside potential exists if profitability targets are met, yet the stock remains speculative given its financial losses and volatile trading pattern.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
